Increased expression of matrix metalloproteinases in the murine zymosan‐induced multiple organ dysfunction syndrome
- 8 July 2004
- journal article
- Published by Wiley in The Journal of Pathology
- Vol. 203 (4), 968-975
- https://doi.org/10.1002/path.1594
Abstract
Matrix metalloproteinases (MMPs) have been implicated as mediators of tissue damage in several inflammatory diseases. Since the multiple organ dysfunction syndrome (MODS) is thought to result from systemic inflammation, overactivation of MMPs could contribute to the organ damage observed. The expression and activity of several MMPs were studied in a murine model for MODS. Sixty mice were given an aseptic intraperitoneal injection of lipopolysaccharide, followed, after 6 days, by zymosan. At days 2, 5, 8, 12, and 16 after the injection of zymosan, the liver, lungs, spleen, and kidneys were collected from groups of mice for either RNA extraction, gelatinase zymography and collagenase (MMP‐1 and ‐13) assays (six mice per time point), or immunohistochemistry (three mice per time point). A group of nine mice did not receive zymosan and acted as controls. The expression of MMP‐2 mRNA in zymosan‐treated mice was strongly up‐regulated in liver tissue only. For MMP‐9, this was the case in all organs examined. Quantitative gelatin zymography demonstrated the near complete absence of any gelatinase activity in tissues from control mice. However, in the liver, lungs, and especially the spleen of zymosan‐treated animals, significantly increased activity of proform and active MMP‐2 and ‐9 was observed with time. Overall, MMP‐1 and ‐13 activities were very low in all samples from the liver and lungs. In the spleen, however, high levels of MMP‐1 and ‐13 were observed in zymosan‐treated animals. Immunohistochemical staining for MMP‐2 was detected in the liver and spleen, but not in lung and kidney tissue of zymosan‐treated animals. Staining for MMP‐9 could be detected in liver, lung, and spleen tissues of zymosan‐treated mice. For both MMPs, staining appeared to be limited to phagocytes. In conclusion, the data suggest a role for MMPs, especially MMP‐9, in the pathogenesis of MODS. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 33 references indexed in Scilit:
- Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patientsCritical Care Medicine, 2003
- Steady progression of osteoarthritic features in the canine groove modelOsteoarthritis and Cartilage, 2002
- Accumulation of Advanced Glycation End Products Decreases Collagen Turnover by Bovine ChondrocytesExperimental Cell Research, 2001
- Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the ratCritical Care Medicine, 2001
- Regulation of Matrix Metalloproteinases and Their Inhibitor Genes in Lipopolysaccharide-Induced Endotoxemia in MiceThe American Journal of Pathology, 2000
- Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosisExpert Opinion on Investigational Drugs, 2000
- A MATRIX METALLOPROTEINASE INHIBITOR PREVENTS PROCESSING OF TUMOR NECROSIS FACTOR α (TNFα) AND ABROGATES ENDOTOXIN-INDUCED LETHALITYShock, 1997
- Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndromeCritical Care Medicine, 1996
- Matrix metal loproteinases and the development of cancerChemistry & Biology, 1996
- VOLATILE ANESTHETIC MODULATION OF LUNG INJURY AND OUTCOME IN A MURINE MODEL OF MULTIPLE ORGAN DYSFUNCTION SYNDROMEShock, 1995